Articles from Valo Health, Inc.

Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced a strategic collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to advance therapeutic discovery in Parkinson’s disease and related disorders. The partnership will leverage Valo’s AI-enabled human causal biology platform to identify and validate novel disease targets and its closed loop discovery platform to rapidly generate preclinical compounds. The partnership includes upfront and potential milestone payments totaling up to over 3 billion dollars, as well as royalties and R&D funding.

Valo Health, Inc. (“Valo”), a company using human data and AI to rapidly discover and develop new medicines, today announced that it has been awarded a research grant from The Michael J. Fox Foundation (MJFF) as part of its Targets to Therapies Initiative, which aims to expand the number of promising druggable biological targets in Parkinson’s disease (PD). Valo was selected for its expertise in leveraging robust human data sets and advanced AI-enabled analytical tools to understand the underlying causes of disease and prioritize targets for new medicines.

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced the appointment of Peggy Dalicandro as Vice President, Head of Human Resources. In this newly created role, Dalicandro will shape Valo’s human capital strategy, lead talent acquisition, and support the scaling of the company.

Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable. The research collaboration will leverage decades of comprehensive, HIPAA-compliant, fully de-identified patient-level data from the nference federated AI network to enhance the capabilities of Valo’s Opal Computational Platform™, enabling advances in the discovery and development of drug targets and precision medicines.